Literature DB >> 11735343

Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.

V R Arruda1, P A Fields, R Milner, L Wainwright, M P De Miguel, P J Donovan, R W Herzog, T C Nichols, J A Biegel, M Razavi, M Dake, D Huff, A W Flake, L Couto, M A Kay, K A High.   

Abstract

A potential consequence of systemic administration of viral vectors is the inadvertent introduction of foreign DNA into recipient germ cells. To evaluate the safety of in vivo recombinant adeno-associated virus (rAAV) mediated gene transfer approaches for hemophilia B, we explored the risk of germline transmission of vector sequences following intramuscular (IM) injection of rAAV in four species of male animals (mouse, rat, rabbit and dog). In vector biodistribution studies in mice and rats, there is a dose-dependent increase in the likelihood that vector sequences can be detected in gonadal DNA using a sensitive PCR technique. However, in dogs DNA extracted from semen is negative for vector sequences. To address this discrepancy, studies were done in rabbits, and both semen and testicular DNAs were analyzed for the presence of vector sequences. These studies showed that no AAV vector sequences were detected in DNA extracted from rabbit semen samples collected at time points ranging from 7 to 90 days following IM injection of 1 x 10(13) vector genomes rAAV (vg) per kg. In contrast, DNA extracted from gonadal tissue was positive for vector sequences, but the positive signals diminished in number and strength with time. By FISH analysis, AAV signals were localized to the testis basement membrane and the interstitial space; no intracellular signal was observed. We observed similar findings following hepatic artery administration of rAAV in rats and dogs, suggesting that our findings are independent of the route of administration of vector. Attempts to transduce isolated murine spermatogonia directly with AAV-lacZ were unsuccessful. In clinical studies human subjects injected IM with an AAV vector at doses up to 2 x 10(12) vg/kg have shown no evidence of vector sequences in semen. Together, these studies suggest that rAAV introduced into skeletal muscle or the hepatic artery does not transduce male germ cells efficiently. We conclude that the risk of inadvertent germline transmission of vector sequences following IM or hepatic artery injection of AAV-2 vectors is extremely low.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735343     DOI: 10.1006/mthe.2001.0491

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

Review 1.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.

Authors:  Federico Mingozzi; Jörg Schüttrumpf; Valder R Arruda; Yuhong Liu; Yi-Lin Liu; Katherine A High; Weidong Xiao; Roland W Herzog
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

4.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 5.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

Authors:  Lixin Wang; Eric Dobrzynski; Alexander Schlachterman; Ou Cao; Roland W Herzog
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 7.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

8.  Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors:  Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal:  Methods Mol Biol       Date:  2014

9.  Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

Authors:  Patricia Favaro; Harre D Downey; J Shangzhen Zhou; J Fraser Wright; Bernd Hauck; Federico Mingozzi; Katherine A High; Valder R Arruda
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

Review 10.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.